

FIG.1

1050220 "45T3/250





FIG.2

Figure. 3


Pharmacokinetic parameters of UDCA in human
After an oral administration of liquid formulation of UDCA
Diagram of the mean (n=5) for Group I
Group I: Dose 600 mg. as solution




* Each bile acid was detected with standard procedure by LC-1500 Series HPLC
System of Jasco equipped with 3 α -HSD(3 α -hydroxysterol dehydrogenase) column

Figure. 4

Pharmacokinetic parameters of UDCA in human
After an oral administration of liquid formulation of UDCA
Diagram of the mean ($n=5$) for Group II
Group II : Dose 600 mg as syrup



* Each bile acid was detected with standard procedure by LC-1500 Series HPLC System
of JASCO equipped with 3 α -HSD(3 α - hydroxysteroid dehydrogenase) column



H. pylori cultured from Columbia medium pictured by
Transmission Electron Microscope

Figure 5A

1. The first part of the paper is devoted to a review of the literature on the topic. It starts with a general overview of the field, followed by a more detailed discussion of the specific issues raised in the title. The author then presents his own findings, which are based on a series of experiments. These experiments were designed to test the hypotheses derived from the literature review. The results of these experiments are presented in a series of tables and figures. Finally, the author discusses the implications of his findings for the field as a whole.



Figure 5B

BEST AVAILABLE COPY

105020-4518760




72hrs, after H. pylori treated with UDCA & bismuth citrate
pictured by Transmission Electron Microscope

Figure 5C


UDCA 020" 45T24.690

Fig.6: NMR data for UDCA in the liquid formulation dosage form:

this data shows that this UDCA is absolutely free UDCA



HPLC for UDCA in the liquid formulation dosage form.



File name : USG0726001.CH1

Info :
GG25STAR250UD5---DW EXT


Vial # = 1 Rack # = 1
Injection Date : 26-Jul-2000 16:48:10
Curr. Date : 30-Jan-2001 17:39:30
User : PRIME
Group : DATA
Acquisition Time : 43.85 [min]
Control Method :
Code of system chromatographic : SYSTEM_1

#	Name	RT	Area[.Sec]	%Area
1	UDCA	14.7423980777.50	99.4	
2	CDCA	30.483	25335.25	0.6

Total Area of Peak = 4006112.75 [.Sec]
Injection Volume = 10.00 ul

HPLC for standard UDCA

Fig. 8



File name : UDCA724003.CH1

Info :
UDCA 500mg/100ml in MeOH

Vial # = 3 Rack # = 1
Injection Date : 24-Jul-2000 17:20:10
Curr. Date : 30-Jan-2001 17:56:14
User : PRIME
Group : DATA
Acquisition Time : 70.00 [min]
Control Method :
Code of system chromatographic : SYSTEM_1


#	Name	RT	Area[.Sec]	%Area
1	UDCA	15.1679092512.25	98.4	
2	CDCA	30.442	99157.50	1.1
3	GLCA	37.675	34224.00	0.4
4	LCA	50.167	17410.75	0.2

Total Area of Peak = 9243304.50 [.Sec]
Injection Volume = 10.00 ul

20000724003.CH1

◀ Abstracted diagram for the culture method ▶


(i) Method with the various pH values.



Plates were incubated microaerophilically at 37°C for 72 hours.

Figure 9


(ii) Method with the various concentrations.



Plates were incubated microaerophilically at 37°C for 72 hours.

Figure 10

(iii) Method with the various concentrations
+ various incubation time



Plates were incubated microaerophilically at 37°C for 72 hours.

Figure 11